Dr Kathryn Williams

BMed(Sci) MBBS(Hons 1), PhD, FRACP
Senior Lecturer, Medicine, Nepean Clinical School

Telephone 02 4734 4754
Fax 02 4734 1817

Map

Biographical details

Kathryn is a Senior Lecturer at the University of Sydney and the Adult Clinical Lead for the Family Obesity Services in the Nepean-Blue Mountains Local Health District. She is also an HVMO at Royal Prince Alfred Hospital and a Clinical Investigator at the Boden Institute. She works as an endocrinologist in private practice.

Kathryn completed her medical training in 2001 at the University of New South Wales and has also completed a PhD in 2016, examining the relationship between type 2 diabetes and non-alcoholic fatty liver disease. She has a strong interest in diabetes and metabolic health. She also has an interest in the health of aboriginal and torres strait islander peoples, previously working at the Aboriginal Medical Service in Redfern from 2015-2016. She has been the Unit of Study Coordinator for the Diabetes Management and Advanced Diabetes Management units of study for the Metabolic Health Postgraduate Program from 2014-2016.

Selected grants

2016

  • Kick Start Grants Program 2017; Williams K; Sydney Medical School/Kickstart Grant.
  • Research in Metabolic Medicine; Twigg S, Williams K; Sydney Medical School Foundation/Foundation Grant.

2014

  • A phase 3, randomized, double-blind, placebo-controlled, 26-week multicentre study with a 78-week extension to evaluate the efficacy and safety of ertugliflozin in subjects with type 2 diabetes mellitus and inadequate glycemic control on metformin monother; Williams K, Caterson I; Merck Sharp & Dohme (Australia) Pty Ltd/Clinical Trial Research Agreement.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Williams, K., Sullivan, D., Veillard, A., O'Brien, R., George, J., Jenkins, A., Young, S., Ehnholm, C., Duffield, A., Twigg, S., Keech, A. (2016). Low alanine aminotransferase levels and higher number of cardiovascular events in people with Type 2 diabetes: analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetic Medicine, 33(3), 356-364. [More Information]
  • Williams, K., Sullivan, D., Nicholson, G., George, J., Jenkins, A., Januszewski, A., Gebski, V., Manning, P., Tan, Y., Donoghoe, M., Buizen, L., Twigg, S., Keech, A., et al (2016). Opposite associations between alanine aminotransferase and γ-glutamyl transferase levels and all-cause mortality in type 2 diabetes: Analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Metabolism: Clinical and Experimental, 65(5), 783-793. [More Information]
  • Williams, K., Burns, K., Constantino, M., Shackel, N., Prakoso, E., Wong, J., Wu, T., George, J., McCaughan, G., Twigg, S. (2015). An association of large-fibre peripheral nerve dysfunction with non-invasive measures of liver fibrosis secondary to non-alcoholic fatty liver disease in diabetes. Journal of Diabetes and Its Complications, 29(8), 1240-1247. [More Information]
  • Williams, K., Vieira de Ribeiro, A., Prakoso, E., Veillard, A., Shackel, N., Brooks, B., Bu, Y., Cavanagh, E., Raleigh, J., McLennan, S., McCaughan, G., Keane, F., Gorrell, M., Twigg, S., et al (2015). Circulating Dipeptidyl Peptidase-4 Activity Correlates with Measures of Hepatocyte Apoptosis and Fibrosis in NAFLD in Type 2 Diabetes Mellitus and Obesity: A Dual Cohort Cross-Sectional Study. Journal of Diabetes, 7(6), 809-819. [More Information]
  • Williams, K., Vieira de Ribeiro, A., Prakoso, E., Veillard, A., Shackel, N., Bu, Y., Brooks, B., Cavanagh, E., Raleigh, J., McLennan, S., McCaughan, G., Keane, F., Twigg, S., Gorrell, M., et al (2015). Lower serum fibroblast activation protein shows promise in the exclusion of clinically significant liver fibrosis due to non-alcoholic fatty liver disease in diabetes and obesity. Diabetes Research and Clinical Practice, 108(3), 466-472. [More Information]
  • Fuller, N., Caterson, I., Sainsbury, A., Denyer, G., Fong, M., Gerofi, J., Baqleh, K., Williams, K., Lau, N., Markovic, T. (2015). The effect of a high-egg diet on cardiovascular risk factors in people with type 2 diabetes: the Diabetes and Egg (DIABEGG) study-a 3-mo randomized controlled trial. The American Journal of Clinical Nutrition, 101(4), 705-713. [More Information]
  • Fuller, N., Williams, K., Shrestha, R., Ahern, A., Holzapfel, C., Hauner, H., Jebb, S., Caterson, I. (2014). Changes in physical activity during a weight loss intervention and follow-up; a randomized controlled trial. Clinical Obesity, 4(3), 127-135. [More Information]
  • Williams, K., Shackel, N., Gorrell, M., McLennan, S., Twigg, S. (2013). Diabetes and Nonalcoholic Fatty Liver Disease: A Pathogenic Duo. Endocrine Reviews, 34(1), 84-129. [More Information]

2016

  • Williams, K., Sullivan, D., Veillard, A., O'Brien, R., George, J., Jenkins, A., Young, S., Ehnholm, C., Duffield, A., Twigg, S., Keech, A. (2016). Low alanine aminotransferase levels and higher number of cardiovascular events in people with Type 2 diabetes: analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetic Medicine, 33(3), 356-364. [More Information]
  • Williams, K., Sullivan, D., Nicholson, G., George, J., Jenkins, A., Januszewski, A., Gebski, V., Manning, P., Tan, Y., Donoghoe, M., Buizen, L., Twigg, S., Keech, A., et al (2016). Opposite associations between alanine aminotransferase and γ-glutamyl transferase levels and all-cause mortality in type 2 diabetes: Analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Metabolism: Clinical and Experimental, 65(5), 783-793. [More Information]

2015

  • Williams, K., Burns, K., Constantino, M., Shackel, N., Prakoso, E., Wong, J., Wu, T., George, J., McCaughan, G., Twigg, S. (2015). An association of large-fibre peripheral nerve dysfunction with non-invasive measures of liver fibrosis secondary to non-alcoholic fatty liver disease in diabetes. Journal of Diabetes and Its Complications, 29(8), 1240-1247. [More Information]
  • Williams, K., Vieira de Ribeiro, A., Prakoso, E., Veillard, A., Shackel, N., Brooks, B., Bu, Y., Cavanagh, E., Raleigh, J., McLennan, S., McCaughan, G., Keane, F., Gorrell, M., Twigg, S., et al (2015). Circulating Dipeptidyl Peptidase-4 Activity Correlates with Measures of Hepatocyte Apoptosis and Fibrosis in NAFLD in Type 2 Diabetes Mellitus and Obesity: A Dual Cohort Cross-Sectional Study. Journal of Diabetes, 7(6), 809-819. [More Information]
  • Williams, K., Vieira de Ribeiro, A., Prakoso, E., Veillard, A., Shackel, N., Bu, Y., Brooks, B., Cavanagh, E., Raleigh, J., McLennan, S., McCaughan, G., Keane, F., Twigg, S., Gorrell, M., et al (2015). Lower serum fibroblast activation protein shows promise in the exclusion of clinically significant liver fibrosis due to non-alcoholic fatty liver disease in diabetes and obesity. Diabetes Research and Clinical Practice, 108(3), 466-472. [More Information]
  • Fuller, N., Caterson, I., Sainsbury, A., Denyer, G., Fong, M., Gerofi, J., Baqleh, K., Williams, K., Lau, N., Markovic, T. (2015). The effect of a high-egg diet on cardiovascular risk factors in people with type 2 diabetes: the Diabetes and Egg (DIABEGG) study-a 3-mo randomized controlled trial. The American Journal of Clinical Nutrition, 101(4), 705-713. [More Information]

2014

  • Fuller, N., Williams, K., Shrestha, R., Ahern, A., Holzapfel, C., Hauner, H., Jebb, S., Caterson, I. (2014). Changes in physical activity during a weight loss intervention and follow-up; a randomized controlled trial. Clinical Obesity, 4(3), 127-135. [More Information]

2013

  • Williams, K., Shackel, N., Gorrell, M., McLennan, S., Twigg, S. (2013). Diabetes and Nonalcoholic Fatty Liver Disease: A Pathogenic Duo. Endocrine Reviews, 34(1), 84-129. [More Information]

To update your profile click here. For support on your academic profile contact .